An 8-month trial in mostly females (17/18) with #obesity & type 2 #diabetes, shows that those randomized to an *intensive* #lifestyle intervention (n=10) e.g. had:
The standard group received "regular" (ADA-guided) instructions on diet & activity.
The intensive lifestyle group had:
⦿ weekly education sessions,
⦿ ⬇️ kcal intake by 500/d &
⦿ 4 x 60-min supervised progressively 📈harder – both resistance & endurance! – training sessions
2/
Energy intake was adjusted to ⬇️ Bw by >10% in 6 months.
The lifestyle intervention was overall quite intensive, & frequent face-to-face contact may have facilitated adherence:
Attendance was 92-98% – possibly facilitated by the rather small sample size, but still impressive
3/
The authors highlight that employers now often provide wellness programs to improve employee health & productivity – 84% of large U.S. companies have this.
This should also target #sleep of course, which unfortunately was not mentioned or measured in the present paper
(4/)
The intensive intervention also ⬆️ the expression of genes involved in mitochondrial oxidation/function & NAD signaling, in skeletal #muscle.
In an oral glucose test, they found plasma glucose & insulin concentrations only ⬇️ in the intense lifestyle group (by ~20-25%)
(5/)
Just to highlight how impressive the successive #weightloss was in the intensive #lifestyle vs. standard-of-care group in this trial – over the course of the 8-month intervention period – we can add a screenshot of one of their supplemental figures:
(6/n)
• • •
Missing some Tweet in this thread? You can try to
force a refresh
The @AnnalsofIM study included all cases in those age 5-39 y (overall incidence was 1 per 30 000 - 200 000 doses), but via U.S. (active) VSD & (passive) VAERS reporting systems.
However, in the U.S., short doses intervals have been used (e.g. 3 wks for Pfizer 1-2)
⦿ Preliminärt ger 3 vaccindoser ~70-75% skydd mot symptomatisk #COVID19 orsakad av Omicron
- åtminstone ~2 veckor efter dos 3 & hos yngre
Därmed antas vaccinskyddet mot svår C19 vara än högre
Trista nyheter-> 🧵
2/ Trista nyheter:
I jämförelse med smittsamma Delta tycks Omicron, *preliminärt*:
⬆️ Reinfektionsrisken 5x (3.4-7.8x) för de med tidigare COVID-19
⬆️ ~2 ggr oddsratio att föra smittan vidare till nära kontakter
⬆️ ~3 ggr oddsratio att föra smittan vidare till hushållskontakter
3/ Trista nyheter:
*preliminära*
⦿ ~22% kontra tidigare 11% risk att en hushållskontakt smittas (secondary attack rate; SAR)
⦿ Smittan växer nu med dubblering var 2.5:e dag i Storbritannien – beräknas kunna ta över (dvs. majoritet av fallen) om någon vecka i Storbritannien.
2/ Reinfektioner är som regel - ej alltid - mildare.
"Reinfections had 90% lower odds of resulting in hospitalization or death than primary infections"
- Omicrons effekter ännu oklar, men ⬆️ reinfektionsrisken
-Vaccinering därmed viktigt för denna grupp nejm.org/doi/full/10.10…
3/ Att reinfektioner (~2a exponering) ger mildare förlopp är jämförbart med hur vaccinen - fast via säker 1:a exponering för virusprotein - sänker risken för allvarlig COVID-19.
Oklart: Vissa tror att 2, särskilt 3 vaccindoser, kan ge hyfsat skydd mot allvarlig C19 av Omicron
->
Pulmonary #embolism (lung blood clot) was >10 times more common after #SARSCoV2 infection (COVID19; ~15x over background rate), vs after getting #Pfizer's or #AstraZeneca's vaccine (~1.2x> background)
2) First of all – as the authors note – in those #vaccinated against COVID-19, "thrombosis, thrombocytopenia, and thrombosis with thrombocytopenia were very rare events."
3) Data from 1.9 Million (M) recipients of AstraZeneca, ~1.7 M of Pfizer, and ~300k COVID-19 cases (few old) – compared with ~2.3 M in the general population.
These cohorts were used to calculate the observed incidence vs. background (SIR) or observed vs. expected # of cases.